Skip to main content
Home
Articles
Latest Issue
Issue Archive
Online First
Special Issues
Categories
Anemia Resources
HOPA Corner
Web Exclusives
All Web Exclusives
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Case-Based Exchanges
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Biosimilar Resources
Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
Voices From ASCO 2025
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
Quick Quiz
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Online First
Special Issues
Categories
Anemia Resources
HOPA Corner
Web Exclusives
All Web Exclusives
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Case-Based Exchanges
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Biosimilar Resources
Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
Voices From ASCO 2025
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
Quick Quiz
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
Editorial Board
Editorial Process
Advertising Policy
Advertise
Multiple Myeloma
IKEMA Study: Isatuximab plus Carfilzomib and Dexamethasone in Patients with RRMM
Read More
Multiple Myeloma
In Patients with RRMM, Idecabtagene Vicleucel, a BCMA-Directed CAR T-Cell Therapy: CRB-401 Study Updates
Read More
Multiple Myeloma
CARTITUDE-1: In Patients with RRMM, Ciltacabtagene Autoleucel, a BCMA-Directed Chimeric Antigen Receptor T-Cell Therapy
Read More
Multiple Myeloma
In Patients with RRMM Teclistamab, a BCMA × CD3 Bispecific Antibody: Phase 1 Study Updates
Read More
Multiple Myeloma
,
Monoclonal Antibodies
In Patients with RRMM, REGN5458, a BCMA × CD3 Bispecific Monoclonal Antibody, Induces Deep and Durable Responses
Read More
Multiple Myeloma
APOLLO: In Patients with RRMM, Daratumumab plus Pomalidomide and Dexamethasone versus Pomalidomide and Dexamethasone Alone
Read More
Multiple Myeloma
Ixazomib, Daratumumab, and Low-Dose Dexamethasone Induction in Frail, Elderly Patients with NDMM
Read More
Multiple Myeloma
CANDOR Study: Subgroup Analysis of Carfilzomib and Dexamethasone with or without Daratumumab in RRMM
Read More
Multiple Myeloma
Belantamab Mafodotin Combined with Pomalidomide and Dexamethasone for RRMM: A Dose-Finding Study
Read More
Multiple Myeloma
DREAMM-2 Study Evaluated Belantamab Mafodotin in Patients with RRMM: Prior Therapy Analysis
Read More
1
2
3
4
Page 1 of 4
Results 1 - 10 of 31
